Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.48 |
| ▸ | MMP9 | P14780 | 12/20 | 0.48 |
| ▸ | MMP1 | P03956 | 11/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397317 | 0.92 | MMP13 (0.51) | MMP13MMP9MMP1LMNACXCR3 | |
| SCHEMBL8762678 | 0.92 | MMP1 (0.49) | MMP13MMP9MMP1LMNACXCR3 | |
| SCHEMBL7461641 | 0.91 | KEAP1 (0.46) | MMP13MMP9MMP1LMNACXCR3 | |
| SCHEMBL7457670 | 0.91 | MMP9 (0.49) | MMP13MMP9MMP1LMNACXCR3 | |
| SCHEMBL6528689 | 0.90 | CXCR3 (0.45) | MMP13MMP9MMP1LMNACXCR3 | |
| SCHEMBL7458056 | 0.86 | CXCR3 (0.48) | LMNACXCR3HPGDOPRK1OPRM1 | |
| SCHEMBL2575788 | 0.85 | MAPT (0.46) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL2576472 | 0.85 | KMT2A (0.44) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL2578877 | 0.85 | MMP13 (0.44) | MMP13MMP9MMP1CXCR3 | |
| SCHEMBL6526546 | 0.83 | HPGD (0.43) | MMP13MMP9MMP1LMNACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0810209-B1 | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | SEARLE & CO (US) | 2002-06-05 | — | — | EP | claimed |
| US-7226932-B2 | Self-emulsifying drug delivery system | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040048934-A1 | Self-emulsifying drug delivery system | G.D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048934-A1 | Self-emulsifying drug delivery system | LIPA, CEL, LSS | MMP13 778/4885MMP9 2920/4885MMP1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.